trending Market Intelligence /marketintelligence/en/news-insights/trending/YAdzylb87KxpiXTj6KX9IA2 content esgSubNav
In This List

Relmada's board approves 1-for-4 reverse split, plans to list on Nasdaq

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Relmada's board approves 1-for-4 reverse split, plans to list on Nasdaq

Relmada Therapeutics Inc.'s board approved a 1-for-4 reverse split of the company's capital stock ahead of a planned listing on the Nasdaq Capital Market.

The reverse split will become effective Sept. 30, and the New York-based company's common stock will begin trading on a split-adjusted basis the same day.

Following the reverse split, the company's authorized shares of common stock will be reduced from about 200 million to about 50 million, and it will have about 9,893,628 outstanding common stock shares.

The company is listed on the OTCQB, a stock market for over-the-counter securities.